Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Income towards Parent Company (2022 - 2025)

Historic Income towards Parent Company for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$38.3 million.

  • Stoke Therapeutics' Income towards Parent Company fell 4508.89% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 13826.23%. This contributed to the annual value of -$88.7 million for FY2024, which is 1538.26% up from last year.
  • Per Stoke Therapeutics' latest filing, its Income towards Parent Company stood at -$38.3 million for Q3 2025, which was down 4508.89% from -$23.5 million recorded in Q2 2025.
  • Stoke Therapeutics' Income towards Parent Company's 5-year high stood at $112.9 million during Q1 2025, with a 5-year trough of -$38.3 million in Q3 2025.
  • Its 4-year average for Income towards Parent Company is -$16.3 million, with a median of -$25.7 million in 2024.
  • The largest annual percentage gain for Stoke Therapeutics' Income towards Parent Company in the last 5 years was 52799.35% (2025), contrasted with its biggest fall of 4508.89% (2025).
  • Quarter analysis of 4 years shows Stoke Therapeutics' Income towards Parent Company stood at -$25.7 million in 2022, then fell by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then plummeted by 258.95% to -$38.3 million in 2025.
  • Its Income towards Parent Company was -$38.3 million in Q3 2025, compared to -$23.5 million in Q2 2025 and $112.9 million in Q1 2025.